Company Directory - Xlear, Inc.
Company Details - Xlear, Inc.
Xlear, Inc.
WebsiteXlear is a company that produces all‐natural nasal sprays designed to clear congestion and support sinus health.
CCI Score
CCI Score: Xlear, Inc.
-18.02
0.02%
Latest Event
DOJ Dismissal of FTC Lawsuit Highlights Xlear's Aggressive Legal and Political Posturing
The dismissal of the FTC lawsuit against Xlear underscores the company’s contentious stance on regulatory oversight and its aggressive rhetoric against government interventions, which critics argue undermines consumer protection and accountability.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ENABLER
Xlear, Inc. is currently rated as an Enabler.
Latest Events
- MAR112025
The dismissal of the FTC lawsuit against Xlear underscores the company’s contentious stance on regulatory oversight and its aggressive rhetoric against government interventions, which critics argue undermines consumer protection and accountability.
-20
Public and Political Behavior
March 26
Xlear’s public messaging in the aftermath of the FTC lawsuit dismissal reflects a politically charged narrative in which the company portrays government regulatory actions as censorship. This aggressive political rhetoric, while couched as a defense of 'science', may be seen as a strategic effort to undermine public accountability and regulatory oversight, thereby challenging the norms of responsible corporate behavior.
-30
Business Practices and Ethical Responsibility
March 26
The FTC lawsuit against Xlear originated from allegations that the company made unsubstantiated claims regarding its nasal spray’s effectiveness against COVID-19. Although the dismissal of the case eliminates immediate penalties, the prolonged legal battle and the company's insistence on a narrative of regulatory overreach raise concerns about its commitment to ethical business practices and consumer protection.
- FEB032025
Nathan Jones, CEO of Xlear, Inc., submitted testimony to the Senate Committee on Health, Education, Labor and Pensions in support of Robert F. Kennedy Jr.'s nomination as Secretary of Health and Human Services, showcasing executive political engagement and a commitment to progressive policy reforms in healthcare.
+70
Executive Political Engagement
March 26
The CEO of Xlear, Inc. used his platform to submit testimony endorsing RFK Jr.'s nomination for HHS Secretary, which signals a proactive engagement in the political process. This executive political engagement reflects a commitment to transparency and progressive values that stand in opposition to authoritarian tendencies. By speaking out in a formal Senate hearing, Jones leverages corporate clout in a manner that supports democratic processes and counteracts the concentration of power linked to authoritarian practices.
- OCT292021
Xlear Inc. is facing a civil enforcement action by the Department of Justice and the Federal Trade Commission for allegedly making unsubstantiated claims that their nasal spray could prevent or treat COVID-19, thereby deceiving consumers during a public health crisis.
-40
Public and Political Behavior
March 26
Xlear's misleading marketing claims contributed to public misinformation in a time of crisis, undermining trust in public health measures. This behavior negatively impacts public and political discourse by eroding the integrity of information during critical public health emergencies.
-60
Business Practices and Ethical Responsibility
March 26
The company is accused of engaging in unethical business practices by promoting unproven health benefits for its nasal spray product. Such deceptive advertising not only violates consumer protection laws but also exploits public health anxieties for profit.
- OCT282021
The FTC has filed a lawsuit against Xlear, Inc. for falsely claiming that its nasal sprays offer protection against COVID-19. Despite a July 2020 warning letter, the company continued to promote unsubstantiated claims across various media channels, misleading consumers and undermining public trust in health information.
-70
Business Practices and Ethical Responsibility
March 26
Xlear, Inc. engaged in unethical business practices by repeatedly making unsubstantiated health claims regarding its nasal sprays, despite prior warnings from regulatory bodies. This behavior undermines consumer protection and violates federal guidelines, reflecting a disregard for ethical responsibility in business practices.
FTC Sues Utah-based Company for Falsely Claiming Its Nasal Sprays Can Prevent and Treat COVID-19
-65
Media Influence and Propaganda
March 26
Xlear, Inc. leveraged various media platforms—including websites, social media channels, and sponsored content—to amplify its false health claims. This misuse of media as a tool for disseminating misleading information contributed to public misinformation and undermined informed public discourse.
FTC Sues Utah-based Company for Falsely Claiming Its Nasal Sprays Can Prevent and Treat COVID-19
- OCT282021
On October 28, 2021, the FTC filed a lawsuit against Xlear, Inc. for making deceptive claims that its saline nasal sprays could prevent or treat COVID-19. The action highlighted the company’s unethical business practices by promoting unsubstantiated health benefits, thereby misleading consumers and bypassing regulatory safeguards.
-40
Business Practices and Ethical Responsibility
March 26
Xlear, Inc. engaged in unethical business practices by making false and misleading claims about the efficacy of its nasal spray in preventing or treating COVID-19. This deception not only violates consumer protection laws but may also undermine public trust in regulatory oversight and scientific research during a critical public health crisis. Such actions contribute to a broader pattern of corporate misconduct that can indirectly weaken democratic accountability.
- OCT282021
The FTC has filed a lawsuit against Xlear Inc. for making unsupported claims that its nasal sprays can prevent and treat COVID-19, resulting in allegations of deceptive advertising and misleading consumers. The company's rhetoric framing government actions as paternalistic and anti-science further undermines public trust in health institutions.
-70
Business Practices and Ethical Responsibility
March 26
Xlear engaged in deceptive advertising by promoting its nasal sprays as an effective way to prevent and treat COVID-19 without appropriate, well-controlled clinical evidence. The decision to persist with these claims in the face of FTC warnings indicates a clear disregard for ethical business practices and consumer protection.
-50
Public and Political Behavior
March 26
Xlear's public communications, including statements that challenge government guidance and claim that regulatory measures suppress beneficial scientific discourse, reflect a concerning misuse of political rhetoric. This approach not only undermines public trust in health institutions but also aligns with narratives that fuel political polarization.
Alternatives
Bagsværd, Denmark
18.81
New Brunswick, United States
0.00
Cincinnati, USA
-6.73
Leverkusen, Germany
-8.11
Corporation
0.00
Corporation
-12.69
Corporation
-16.13
Brentford, United Kingdom
18.03
Tokyo, Japan
-7.42
North Chicago, United States
-31.53
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 325998
- All Other Miscellaneous Chemical Product and Preparation Manufacturing
- 424210
- Drugs and Druggists' Sundries Merchant Wholesalers